Lebwohl, Mark, Hervé Bachelez, Kenneth Gordon, Tianshuang Wu, Michael Chen, Blair Kaplan, and Kim Papp. 2023. “Maintenance of Clinical Response With Continued Risankizumab Treatment for Moderate-to-Severe Psoriasis Through 304 Weeks: Interim Analysis of the LIMMitless Open-Label Extension Study”. SKIN The Journal of Cutaneous Medicine 7 (6):s258. https://doi.org/10.25251/skin.7.supp.258.